We’re pleased to announce the closing of our merger with Accovion, a leading European full-service CRO headquartered in Frankfurt (Eschborn), Germany. Bringing these organizations together strengthens our operational and therapeutic expertise in Europe, with strong back-end and front-end services, and expands our footprint to additional countries including Russia, Italy, Czech Republic, Romania, Poland, Spain, France and Ukraine.
Combined with Accovion, Clinipace now has clinical operations and staff in 39 countries. European operations are based in Frankfurt, Munich and Marburg, Germany; Prague, Czech Republic; Krakow, Poland; Timisoara, Romania; Moscow, Russia; Zurich, Switzerland; Milan, Italy; Lyon, France; Madrid, Spain; London, United Kingdom; and Kiev, Ukraine.
“Life science firms, and the CRO industry that serves them, continue to undergo significant change. To be competitive in today’s market, it is important to have, among other things, a strong multi-national scale, broad therapeutic expertise and a better service delivery model. Bringing our companies together substantially enhances our existing European footprint throughout western, central and eastern Europe and enables us to offer a competitive array of global clinical development and regulatory services in these regions. Supported by our technology-amplified dCRO delivery model, we now have a very compelling value proposition for sponsors looking for support in these markets.”
-Jeff Williams, CEO
Together, our company will now be home to nearly 1,000 global staff. Our combined company has managed over 3,000 clinical research studies and more than 300 regulatory and strategic development engagements.
To read today’s announcement, click here.